(Q43283507)

English

Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting

scientific article published on 31 August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 November 2017

Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting (English)

1 reference

Europe PubMed Central

18 November 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

chronic myelomonocytic leukemia

1 reference

based on heuristic

inferred from title

author name string

M Lübbert

1

1 reference

Europe PubMed Central

18 November 2017

H Bertz

2

1 reference

Europe PubMed Central

18 November 2017

R Wäsch

3

1 reference

Europe PubMed Central

18 November 2017

R Marks

4

1 reference

Europe PubMed Central

18 November 2017

B Rüter

5

1 reference

Europe PubMed Central

18 November 2017

R Claus

6

1 reference

Europe PubMed Central

18 November 2017

J Finke

7

1 reference

Europe PubMed Central

18 November 2017

language of work or name

0 references

publication date

31 August 2009

1 reference

Europe PubMed Central

18 November 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

18 November 2017

45

1 reference

Europe PubMed Central

18 November 2017

4

1 reference

Europe PubMed Central

18 November 2017

627-632

1 reference

Europe PubMed Central

18 November 2017

https://scigraph.springernature.com/pub.10.1038/bmt.2009.222

0 references

Epigenetic targets in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Donor lymphocyte infusions for acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

5-AZA-2'-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

MODULATION OF HLA-DR ANTIGENS EXPRESSION IN HUMAN MYELOID LEUKAEMIA CELLS BY CYTARABINE AND 5-AZA-2'-DEOXYCYTIDINE

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

21 January 2018

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

7 January 2021

based on heuristic

inferred from DOI database lookup

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

7 January 2021

based on heuristic

inferred from DOI database lookup

Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term lymphoid-restricted split chimerism after myeloablative allogeneic BMT for bcr-abl+ ALL

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

7 January 2021

based on heuristic

inferred from DOI database lookup

Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.222

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2009.222

1 reference

Europe PubMed Central

18 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

18 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43283507&oldid=1985560953"